Spero Therapeutics, Inc. (SPRO) compared with its closest peers (SER, IBIO, PLRX, RNTX, PMVP): P/E 9.6 vs industry 17.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Serina Therapeutics, Inc. (SER) | $72.65M | -1.0 |
| iBio, Inc. (IBIO) | $71.54M | -0.4 |
| Pliant Therapeutics, Inc. (PLRX) | $71.52M | -0.5 |
| Rein Therapeutics Inc. (RNTX) | $71.52M | -0.6 |
| PMV Pharmaceuticals, Inc. (PMVP) | $70.56M | -0.9 |
| XBiotech Inc. (XBIT) | $69.82M | -1.6 |
| OS Therapies Incorporated (OSTX) | $69.19M | -1.4 |
| MediciNova, Inc. (MNOV) | $68.66M | -5.4 |
| Boundless Bio, Inc. (BOLD) | $68.24M | -0.5 |
| Cypherpunk Technologies Inc. (CYPH) | $67.13M | 16.5 |
| Stock P/E | 9.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -55.7% |
| vs Industry | -43.3% |
SPRO overview · SPRO earnings · SPRO financials · SPRO KPIs · SPRO investor relations · SPRO ownership · SPRO filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.